Drug intelligence / Profile preview

BCM-5021

Development stage: Preclinical
Lead developer: ImmuneCyte Life Sciences
Modality: Cell Therapies
Administration: Intravenous

Overview

BCM-5021 is an autologous tumor-infiltrating lymphocyte (TIL) cell therapy developed by ImmuneCyte Life Sciences for the treatment of solid tumors. The program leverages the company's proprietary X-BACS (X-ray-based Automated Cell Separation) technology to isolate and expand tumor-reactive lymphocytes from the patient's own tumor microenvironment. These expanded T cells are then re-infused into the patient to recognize and eliminate cancer cells through a polyclonal immune response directed at various tumor-associated antigens and neoantigens.

Beyond the preview

Go deeper on BCM-5021.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCM-5021.

Explore the full profile